Youmai Technology Secures Nearly $10M Series A++ Funding Led by Qianji Capital, Receives Class II Medical Device Approval for USKIN-001

VCBeat has learned that Umai Technology, China’s leading internet healthcare platform for dermatology, recently announced the completion of its A++ round of financing, raising nearly $10 million from Cenova Capital. This marks Umai Technology’s second funding round within three months, following its A+ round exclusively invested by Matrix Partners China. Joywise Capital once again served as the exclusive financial advisor for this round.

Meanwhile, it is worth noting that Youmai Technology and the CSID expert team have jointly developedSkin Image Management Software (USKIN-001), obtained the People's Republic of ChinaMedical Device Registration Certificate(Class II), this project was funded by the Open Research Fund (CSID-ORF) of the Chinese Skin Image Database (CSID). The approval of the Class II medical device certificate marks another technological innovation milestone for Umai Technology in digital dermatology applications, following its acquisition of an internet hospital license in April.

UMai Tech has always adhered to"Technological Innovation Improves Skin Health"mission, leveraging the advantage that its core product, the Youmai Doctor APP, has reached over 95% of dermatologists, Umai Technology is working with thousands of dermatologists within its establishedUMai Cloud Hospital...jointly promote the dissemination of professional dermatological knowledge to a broader audience. This time,USKIN-001The practical implementation will further enhance dermatology’s capabilities in image processing, information acquisition, and clinical diagnosis, helping to bridge the “information gap” between different regions and institutions.

UMed Technology has deeply cultivated the dermatology medical sector and has long established“D+B+C”value realization model, is gradually being integratedClinical Data Collection - Patient-Provider Education - Market Promotion - Diagnosis and Treatment Services - Disease-Specific Care Managementthe full-chain pathway. The skin image management software, which has recently obtained the Class II medical device certification, is built upon the Chinese Population Skin Imaging Resource Library. By leveraging internet technologies to facilitate the “flow” of imaging data and bridge “information silos,” it maximizes the utilization efficiency of medical resources, thereby supporting the implementation of policies such as “tiered diagnosis and treatment” and “downward distribution of medical resources.”

This year marks a pivotal period for regulatory approvals and capital market activity in China’s digital therapeutics (DTx) sector; however, a significant number of Chinese DTx companies remain in the clinical or even pre-clinical validation stages. The essence of digital therapeutics lies in modifying users’ lifestyle and health behaviors through behavioral management. As such, DTx is not merely a traditional pharmaceutical or medical device product, but also entails substantial challenges in clinical adoption and market education. Umai Technology has built its strategy around the integration of physicians and patients...Digital Healthcare Ecosystem for DermatologyClosed-loop, which can be further deepened to provide professional services for hundreds of dermatology pharmaceutical companies and skin care consumer goods companiesOne-Stop Digital Marketing Solution, with the support of this financing round, it will also accelerate the development of its dermatological medical infrastructure, providing further solutions for digital therapeutics innovators facing challenges in commercialization and efficacy validation.

More importantly, Youmai Technology will continue to strengthen its efforts in building specialized internet hospitals and managing disease-specific patient journeys. Its one-stop smart skin management platform provides consumer-facing science education, online consultations, and skin health record management, while delivering intelligent skin care solutions that combine precise medication with professional, medical-grade skincare.

Mr. Chang Jiang, Founder of Umai TechnologyStating that over the years of engaging with the dermatologist community, we have gained insights into their needs in education, clinical practice, and value realization, while also deeply understanding the challenges faced by dermatology patients and consumers in science popularization, medical consultation, and daily skincare. Guided by the goal of “building a digital healthcare ecosystem for dermatology,” we have established a professional platform company covering the “D+B+C” (Doctor + Business + Consumer) segments in the dermatology field. From digital marketing and physician brand building to science education, and further to providing smart skin solutions that combine precise medication guidance with professional medical-grade skincare for consumers, we have been committed to improving skin health through technological innovation. Following this round of financing, we will continue to invest in R&D breakthroughs in digital dermatology tools and skin management platforms, striving to realize our vision at an early stage: making the Youmai Index the national skincare index for Chinese people.

Ms. Zhang Min, Managing Director of Cenova Capitalstating that dermatology spans both the medical and consumer sectors, the domestic market has witnessed explosive growth driven by the successive launch of innovative monoclonal antibody drugs and rising consumer demand for efficacy-based skincare products. Leveraging the Youmai Doctor App, which extensively covers dermatologists across China, Youmai has become a highly influential digital platform in dermatology, offering one-stop, medical-grade skin management solutions. We are optimistic about Youmai’s “D+B+C” model in the dermatology sector and believe it will introduce more innovative services and products to the field of dermatological medicine in China. We are pleased to partner with Youmai to support its creation of long-term value within China’s dermatological ecosystem, achieving synergistic win-win outcomes alongside Cenova Capital’s portfolio companies, which are domestic leaders in the layout of medical products, services, and payers.

Mr. Guo Yixin, Managing Director of Hywin CapitalHe stated that digital healthcare has long been integrating with traditional medical services, continuously refining their synergy in terms of accessibility, reliability, and convenience. Given the characteristics of dermatology—namely, its high prevalence, frequent occurrence, and the nature of many conditions as mild, chronic diseases without specific triggers—the field inevitably requires more technologically innovative platforms and approaches to deeply connect physicians, pharmaceutical companies, patients, and skincare brands. We are pleased to see that Umai Technology, while supporting dermatologists in their learning and professional development, is continuously empowering them with tools and services to reach a broader patient base and realize their personal value. By breaking down the inherent barriers of healthcare delivery, Umai Technology is providing both physicians and patients with a more accessible, reliable, and convenient one-stop skin health management platform.

Youmai Technology, established in 2015, is one of the most influential value platforms for dermatologists in China. Its core product, the Youmai Doctor APP, has accumulated over 120,000 users to date, covering more than 95% of dermatologists across China. It is officially recognized by professional institutions such as the Dermatology Branch of the Chinese Medical Doctor Association, the Society of Dermatology and Venereology of the Chinese Medical Association, and the Skin Disease Committee of the China Association of Integrative Medicine as the most professional learning platform for dermatologists in China. Meanwhile, the company operates across the high-potential medical and consumer sectors, providing professional one-stop digital marketing solutions to hundreds of pharmaceutical companies specializing in dermatology and skincare consumer goods companies. It continues to strengthen its capabilities in building specialized internet hospitals and managing disease-specific patient journeys, constructing an ecological closed loop for digital dermatological healthcare centered on an integrated doctor-patient strategy.

Cenova Capital, established in 2010, is one of the earliest professional funds in China dedicated to investment in the healthcare and life sciences sectors, committed to promoting the transformation, upgrading, and innovation of China’s medical industry. Cenova Capital currently manages six healthcare industry funds, with capital commitments from renowned international and domestic institutional investors, including Asian sovereign wealth funds, government agencies, domestic and foreign insurance and financial institutions, and multinational corporations.

Haoyue Capital, established in January 2014, is dedicated to serving as a bridge connecting China’s healthcare sector with capital markets. Its research and transaction coverage spans multiple sub-sectors, including biopharmaceuticals, innovative medical devices, in vitro diagnostics (IVD) and precision medicine, healthcare services, and smart healthcare. The Haoyue Capital team comprises seasoned investment bankers with extensive experience in China’s healthcare industry. By closely monitoring market dynamics and investment trends in the healthcare sector over the long term, the firm publishes weekly healthcare investment updates and special thematic research reports, offering Haoyue’s perspectives on new policies and emerging frontiers.